Eton Pharma Q1 revenue $8.0M (+50% YoY); acquires PKU GOLIKE; submits NDA for ET-400

Eton Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.03 revenue$7,966,000

Q1 2024 revenue $8.0M, up 50% YoY; net loss narrowed to $0.8M from $2.7M.
Acquired U.S. rights to PKU GOLIKE for PKU; market ~$100M; targeting $10M annual sales.
Submitted NDA for ET-400 (hydrocortisone oral solution); potential approval Q1 2025; peak sales >$50M combined.
Launched Nitisinone in Feb 2024; $50M market; cross-selling opportunities with Carglumic Acid and PKU GOLIKE.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Eton Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $8.0 million, net income Net loss for the first quarter of 2024 was $0.8 million, EPS $0.03 per basic and diluted share.

Period: first quarter ended March 31, 2024
Revenue: $8.0 million
Net income: Net loss for the first quarter of 2024 was $0.8 million
EPS: $0.03 per basic and diluted share
Result: reported results

Exact text from the filing

Net revenues for the first quarter of 2024 were $8.0 million compared with $5.3 million in the prior year period, an increase of 50%.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-015686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.